Smith & Nephew Launches Regranex360™ - a New Support Network for Patients Using REGRANEX® (becaplermin) Gel, 0.01%

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): PR Newswire
  • Source:
    PR Newswire US. 10/08/2013.
  • Additional Information
    • Alternate Title:
      TX-Smith&NephewLaunch
    • Subject Terms:
      Texas
    • Abstract:
      FORT WORTH, Texas, Oct. 8, 2013 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the introduction of Regranex360™, a comprehensive new program to support patients in the U.S. using REGRANEX™ Gel. REGRANEX Gel is the first and only FDA-approved platelet-derived growth factor (PDGF) therapy indicated as an adjunct to good ulcer care for the treatment of lower extremity diabetic neuropathic ulcers.1 [ABSTRACT FROM PUBLISHER]